ISRG Intuitive Surgical NASDAQ pre-market Mar 23 2026: $479.93, Meyka B+ on AI

First up: ISRG stock opened pre-market at $479.93 on 23 Mar 2026, trading below its 50-day average and reflecting mixed sentiment around regulatory headlines and AI-driven robotics demand. Investors focus on near-term regulatory risk from stapler safety flags while analysts point to durable revenue growth and strong margins. The company reported recent quarterly EPS of $2.53 and trailing EPS of $7.87, supporting a premium valuation. We examine fundamentals, technicals, analyst price targets, and our AI-focused outlook for Intuitive Surgical, Inc. (NASDAQ: ISRG) in the United States market.

ISRG stock: Earnings and fundamentals

Intuitive Surgical reported revenue of $2.87 billion and EPS of $2.53 for the last quarter, beating consensus estimates and showing revenue growth of 18.8% year over year. The company posts a net margin near 28.38%, trailing EPS $7.87, a market cap of $169.74 billion USD, and a P/E around 60.73, which prices strong growth expectations into the stock.

ISRG stock: Meyka AI grade and model forecast

Meyka AI rates ISRG with a score out of 100: 79.62, Grade B+, Suggestion BUY. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year target of $585.45 USD, implying 21.98% upside from the current price of $479.93; forecasts are model-based projections and not guarantees.

ISRG stock: AI opportunity and sector context

Intuitive sits in the Healthcare sector, Medical – Instruments & Supplies industry, and benefits from long-term secular demand for robotic surgery and AI-driven workflow tools. Adoption in ambulatory surgery centers and software-enabled services are cited as multi-year growth drivers by several analysts, while the company invests roughly 13.03% of revenue in R&D to expand platform applications.

ISRG stock: Risks, regulatory headwinds and insider activity

Regulatory risk is the main near-term headwind after FDA flags on stapler products and a related death reported, which can slow adoption and prompt recalls. Insiders sold shares recently (32,943 shares valued at about $17.28 million in the last quarter), and institutional ownership remains high at about 83.64%, making large reallocations possible if sentiment shifts.

ISRG stock: Technical picture and trading levels

Technicals show RSI near 40.00, an ADX of 32.62 indicating a strong trend, and a 50-day average around $510.39 versus a 200-day average near $510.17, signaling recent underperformance. Key intraday support sits near the day low $475.81 and resistance near the day high $483.04; volatility measures (ATR 13.26) suggest risk-managed position sizing for traders.

ISRG stock: Analyst targets and investor takeaways

Wall Street targets vary: conservative targets cluster near $550.00, consensus around $614.95, and bullish cases at $740.00–$750.00 from select firms. Analysts cite strong margins and durable installed-base economics, but many trimmed near-term targets after safety headlines. For AI-focused investors, the core trade is exposure to robotic automation growth balanced against execution and regulatory risk.

Final Thoughts

Bottom line: ISRG stock trades at $479.93 USD pre-market on 23 Mar 2026, reflecting a mix of strong fundamentals and short-term regulatory uncertainty. The company continues to post solid top-line growth, a net margin near 28.38%, and heavy institutional ownership. Meyka AI rates ISRG with a score out of 100 at 79.62 (B+, Suggestion BUY) and our model projects $585.45 USD in one year, implying 21.98% upside versus current price. Practical outlook: consider a staged entry if you accept the premium P/E near 60.73, watch regulatory updates closely, and use technical levels near $475.81 support for risk control. These views pair AI-sector thesis support for robotic adoption with disciplined risk management. Meyka AI is an AI-powered market analysis platform and this note is for informational purposes only — these grades and forecasts are not guaranteed and do not constitute financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.